Nuclear medicine imaging

Imaging of Soft Tissue Tumors

Volumn , Issue , 2006, Pages 45-59

  Carp, L ^a   Blockx, P P ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846984783     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-30792-3_4     Document Type: Chapter

References (98)

1. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, al-Kaisi N, Miraldi F (1991) Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32(8):1508-1512
2. Aoki J, Watanabe H, Shinozaki T et al (2003) FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 32:133-138
3. Barton DJ, Miller JH, Allwright SJ, Sloan GM (1992) Distinguishing soft tissue hemangiomas from vascular malformations using technetium-labeled red blood cell scintigraphy. Plast Reconstr Surg 89(1):46-52
4. Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF (2004) Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. Am J Roentgenol 182(4):971-974
5. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K (2004) Imaging of advanced neuroendocrine tumors with (18) FFDOPA PET. J Nucl Med 45(7):1161-1167
6. Bender H, Friedrich E, Zamora PO, Biersack HJ (1995) Detection of multidrug resistance with Tc-99m sestamibi. J Nucl Med 36(5):129P (Abstract)
7. Blatt CJ, Hayt DB, Desai M et al (1977) Soft-tissue sarcoma: imaged with technetium-99m pyrophosphate. NY State J Med 77:2118-2119
8. Brant WE, Floyd JL, Jackson DE et al (1987) The radiological evaluation of hepatic cavernous hemangioma. JAMA 257:1063-1070
9. Bredella MA, Caputo GR, Steinbach LS (2002) Value of FDG positron emission tomography in conjunction with MRI for evaluating therapy response in patients with musculoskeletal sarcomas. Am J Roentgenol 179(5):1145-1150
10. Cardona S, Schwarzbach M, Hinz U et al (2003) Evaluation of F-18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29(6):536-541
11. Chauhan UPS, Babbar A, Kashyap R, Prakash R (1992) Evaluation of a DMSA kit for instant preparation of 99mTc-(V)-DMSA for tumour and metastasis scintigraphy. Nucl Med Biol 19:825-830
12. Chew FS, Hudson TM, Enneking WF (1981) Radionuclide imaging of soft tissue neoplasms. Semin Nucl Med XI (4): 266-276
13. Ciarmiello A, Del Vecchio S, Potena MI, Mainolfi C, Carriero MV, Tsuruo T, Marone A, Salvatore M (1995) Tc-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma. J Nucl Med 36(5):129P (Abstract)
14. Citrin DL, McKillop JH (1978) Atlas of technetium bone scans. Saunders, Philadelphia, pp 43-65
15. Cobben DC, Elsinga PH, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL, Hoekstra HJ (2004) Detection and grading of soft tissue sarcomas of the extremities with (18) F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res 10(5):1685-1690
16. Cogswell A, Howman-Giles R, Bergin M (1994) Bone and gallium scintigraphy in children with rhabdomyosarcoma: a 10-year review. Med Pediatr Oncol 22(11):15-21
17. Cox PH, Verweij J, Pillay M, Stoter G, Schonfeld D (1988) Indium-111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma. Eur J Nucl Med 14:50-52
18. Delbeke D (1999) Oncological applications of FDG PET imaging. J Nucl Med 40:1706-1715
19. De Moerloose B, Van de Wiele C, Dhooge C, Philippé J, Speleman F, Benoit Y, Laureys G, Dierckx RA (1999) Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein. Eur J Nucl Med 26:396-403
20. Drane WE (1991) Nuclear medicine techniques for the liver and biliary system. Radiol Clin North Am 29:1129-1151
21. Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, Conrad EU (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 29(9):1149-1154
22. Enneking WF, Chew FS, Springfield DS et al (1981) The role of radionuclide bone-scanning in determining the resectability of soft-tissue sarcomas. J Bone Joint Surg 63:249-257
23. Feldman F, van Heertum R, Manos C (2003) 18-FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 32:201-208
24. Felix EL, Sindelar WF, Bagley DH et al (1975) The use of bone and brain scans as screening procedures in patients with malignant lesions. Surg Gynecol Obstet 141:867-869
25. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, Podoloff DA (1996) Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 37(9):1476-1479
26. Gehring PJ, Hammand PB (1967) The interrelationship between thallium and potassium in animals. J Pharmacol Exp Ther 155:187-201
27. Ginkel RJ van, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AM, Willemsen AT, Vaalburg W, Koop HS (1996) FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 37(6):984-990
28. Ginkel RJ van, Kole AC, Nieweg OE, Molenaar WM, Pruim J, Koops HS, Vaalburg W, Hoekstra HJ (1999) L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. J Nucl Med 40(2):262-267
29. Goshen E, Meller I, Lantsberg S, Sagi A, Moses M, Fuchsbrauner R, Quastel MR (1991) Radionuclide imaging of soft tissue masses with Tc-99m DTPA. Clin Nucl Med 16(9):636-642
30. Goto Y, Ihara K, Kawauchi S, Ohi R, Sasaki K, Kawai S (2002) Clinical significance of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci 7(3):304-312
31. Grufferman S, Gillman MW, Pasternak LR et al (1980) Familial carotid body tumors: case report and epidemiologic review. Cancer 46:2116-2122
32. Hain SF, O'Doherty MJ, Bingham J, Chinyama C, Smith MA (2003) Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun 24(11):1139-1143
33. Hattner RS, White DL (1990) Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. J Nucl Med 31:1844-1846
34. Hattner RS, Huberty JP, Engelstad BL, Gooding CA, Ablin AR (1984) Localization of m-iodo (I-131) benzylguanidine in neuroblastoma. Am J Roentgenol 143:373-374
35. Hoefnagel CA, de Kraker F (1994) Childhood neoplasia. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and treatment, vol 2. Churchill Livingstone, Edinburgh, p 765-777
36. Hoefnagel CA, Voûte PA, Kraker J de, Behrendt H (1987) Scintigraphic detection of rhabdomyosarcoma. Lancet i: 921
37. Hoefnagel CA, Kraker J de, Voûte PA, Behrendt H (1988) Tumor imaging of rhabdomyosarcoma using radiolabeled fragments of monoclonal anti-myosin antibody. J Nucl Med 29:791
38. Hoefnagel CA, Kapucu Ö, de Kraker J, Voûte PA (1993) Radioimmunoscintigraphy using 111In-antimyosin Fab fragments for the diagnosis and follow-up of rhabdomyosarcoma. Eur J Cancer 29A: 2096-2100
39. Hoegerle S, Schneider B, Kraft A, Moser E, Nitzsche EU (1999) Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography. Nuklearmedizin 38(4):127-130
40. Howman-Giles R, Uren RF, Shaw PJ (1995) Thallium-201 scintigraphy in pediatric soft tissue tumors. J Nucl Med 36(8):1372-1376
41. Imaeda T, Seki M, Sone Y, Iinuma G, Kanematsu M, Mochizuki R, Takeuchi S, Nishimoto Y, Shimokawa K (1991) Gallium-67 citrate scintigraphy in the pre-operative evaluation of soft tissue tumors of the extremities. Ann Nucl Med 5(4):127-132
42. Jackson GE, Byrne MJ (1996) Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. J Nucl Med 37(2):379-386
43. Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A (2003) Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med 28(10):815-820
44. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, Dewhirst MW, Prescott DM, Friedman HS, Harrelson JM, Scully SP, Coleman RE (1996) Monitoring of neoadjuvant therapy resonse of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 37(9):1438-1444
45. Kairemo KJA, Wiklund TA, Liewendahl L et al (1990) Imaging of soft tissue sarcomas with In-111-labeled monoclonal antimyosin Fab fragments. J Nucl Med 31:23-31
46. Kaye SB (1988) The multidrug resistance phenotype. Br J Cancer 58:691-694
47. Kim E, Garcia JR, Wong FC, Kim CG, Broussard W, Podoloff DA (1995) Comparison of fluorodeoxyglucose (FDG) PET and Sestamibi (MIBI) SPECT in detection of residual or recurrent musculoskeletal sarcoma. J Nucl Med 36(5):234P (Abstract)
48. Kobayashi H, Sakahara H, Hosono M, Shirato M, Konishi J, Kotoura Y, Yamamuro T, Endo K (1993) Scintigraphic evaluation of tenosynovial giant-cell tumor using technetium-99m (V) - dimercaptosuccinic acid. J Nucl Med 34(10):1745-1747
49. Kobayashi H, Sakahara H, Hosono M, Shirato M, Endo K, Kotoura Y, Yamamuro T, Konishi J (1994) Soft-tissue tumors: diagnosis with Tc-99m (V) dimercaptosuccinic acid scintigraphy. Radiology 190(1):277-280
50. Korkmaz M, Kim EE, Wong F, Haynie T, Wong WH, Tilbury R, Benjamin R (1993) FDG and methionine PET in differentiation of recurrent or residual musculoskeletal sarcomas from posttherapy changes. J Nucl Med 34(5):33P (Abstract)
51. Kostakoglu L, Manicek DM, Divgi CR, Botet J, Healy J, Larson SM, Abdel-Dayem HM (1995) Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. J Nucl Med 22(11):1232-1237
52. Krause T, Hauenstein K, Studier-Fischer B, Schuemichen C, Moser E (1993) Improved evaluation of technetium-99m-red blood cell SPECT in hemangioma of the liver. J Nucl Med 34(3):375-380
53. Krenning EP, Kwekkeboom DJ, Reubi JC, Lamberts SWJ (1994) Somatostatin receptor scintigraphy with (111In-DTPA-d-Phe1) octreotide. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and treatment, vol 2. Churchill Livingstone, Edinburgh, pp 757-764
54. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19(14):3397-3405
55. Kwekkeboom DJ, Van Urk H, Pauw KH et al (1993) Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 43:873-878
56. Lamberts SWJ, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 12:450-482
57. Larson SM, Radey JS, Allen DR et al (1980) Common pathway for tumour cell uptake of gallium-67 and iron-59 via a transferring receptor. J Natl Cancer Inst 64:41-53
58. Lebtahi R, Le Cloirec J, Houzard C et al (2002) Detection of neuroendocrine tumors:99m-Tc-P829 scintigraphy compared with 111-In-pentetreotide scintigraphy. J Nucl Med 43(7):889-895
59. Lepanto PB, Rosenstock J, Littman P, Alavi A, Donaldson M, Kuhl DE (1976) Gallium-67 scans in children with solid tumours. Am J Roentgenol 126:176-186
60. Lin WY, Kao CH, Hsu CY, Liao SQ, Wang SJ, Ueh SH (1994) The role of Tc-99m MDP and Ga-67 imaging in the clinical evaluation of malignant fibrous histiocytoma. Clin Nucl Med 19(11):996-1000
61. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26(1):22-30
62. Lucas JD, O'Doherty MJ, Wong JC, Bingham JB, McKee PH, Fletcher CD, Smith MA (1998) Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 80(3):441-447
63. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH, Smith MA (1999) Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 86(4):550-556
64. Lumbroso JD, Guermazi F, Hartmann O et al (1988) Metaiodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res 271:689-705
65. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD (1993) Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34(2):173-179
66. Menendez LR, Fideler BM, Mirra J (1993) Thallium-201 scanning for the evaluation of osteosarcoma and soft-tissue sarcoma. A study of the evaluation and predictability of the histological response to chemotherapy. J Bone Joint Surg Am 75:526-531
67. Nagaraj N, Ashok G, Waxman A, Kovalevsky M, Youssim C, Forscher C, Rosen G (1995) Clinical usefulness of serial Tc-99m sestamibi scintigraphy in evaluating tumor response to preop chemotherapy in patients with bone and soft tissue sarcomas. J Nucl Med 36(5):129P (Abstract)
68. Noujaim AA, Turner CJ, Van Nieuwenhuyze BM, Terner U, Lentle BC (1981) An investigation of the mechanism of cis-diamine dichloroplatinum (cis-pt) interference with radiogallium uptake in tumors. Aust NZJ Med 11:437
69. Ohta H, Endo K, Konishi J et al (1990) Scintigraphic evaluation of aggressive fibromatosis. J Nucl Med 31:1632-1634
70. Parisi MT, Green MK, Dykes TM, Moraldo TV, Sandler ED, Hattner RS (1992) Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol 10:768-772
71. Pearlman AW (1977) Preoperative evaluation of liposarcoma by nuclear imaging. Clin Nucl Med 2:47-51
72. Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W, Vaalburg W (1999) Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med 26(4):328-332
73. Prakash R, Jena A, Behari V et al (1987) Technetium-99m red blood cell scintigraphy in diagnosis of hepatic hemangioma. Clin Nucl Med 12:235-237
74. Pruim J, Ginkel RJ van, Willemsen ATM, Paans AMJ, Nieweg OE, Kole AC, Hoekstra HJ, Molenaar WM, Visser GM, Schraffordt Koops H, Vaalburg W (1995) Protein synthesis rate (PSR) measured with L-(1-C-11)-tyrosine in soft tissue tumours. J Nucl Med 36(5):217P (Abstract)
75. Reuland P, Koscelniak E, Ruck P, Treuner J, Feine U (1991) Application of an anti-myosin for scintigraphic differential diagnosis of infantile tumors. Int J Rad Appl Istrum (B) 18:89-93
76. Rosso J, Guillon JM, Parrot A, Denis M, Akoun G, Mayaud Ch, Scherrer M, Meignan M (1992) Technetium-99m-DTPA aerosol and gallium-67 scanning in pulmonary complications of human immunodeficiency virus infection. J Nucl Med 33(1):81-87
77. Rubin RA, Lichtenstein GR (1993) Scintigraphic evaluation in liver masses: cavernous hepatic hemangioma. J Nucl Med 34(5):849-852
78. Rufini V, Giordano A, Di Giuda D, Petrone A, Deb G, De Sio L, Donfrancesco A, Troncone L (1995) 123-I MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 39:25-28
79. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, Diederichs CG, Schultheiss M, Kotzerke J, Reske SN (1999) Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a noninvasive determination of biological activity possible? Eur J Nucl Med 26(6):599-605
80. Schwartz HS, Jones CK (1992) The efficacy of gallium scintigraphy. Ann Surg 215:78-82
81. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, Straus LG, Zhang YM (1999) Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 19(2B):1343-1349
82. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al (2000) Clinical value of 18-F-fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 231(3):380-386
83. Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G et al (2001) Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res 21(5):3609-3614
84. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576-585
85. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, Rawwas JB, Castle VP, Sisson JC, Hutchinson RJ (1996) PET Hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37(1):16-21
86. Southee AF, Kaplan WD, Jochelson MS, Gonin R, Dwyer JP, Antman KH, Elias AD (1992) Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med 33(9):1594-1599
87. Stroobants S, Goeminne J, Seegers M et al (2003) 18FDGPositron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39(14):2012-2020
88. Taki J, Sumiya H, Tsuchiya H, Tomita K, Nonomura A, Tonami N (1997) Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. J Nucl Med 38:501-506
89. Taki J, Sumiya H, Asada N, Ueda Y, Tsuchiya H, Tonami N (1998) Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 39:1179-1184
90. Terui S, Terauchi T, Abe H, Fukuma H, Beppu Y, Chuman K, Yokoyama R (1994) On clinical usefulness of TI-201 scintigraphy for the management of malignant soft tissue tumors. Ann Nucl Med 8:55-64
91. Thompson DE, Frost HM, Hendrick JW et al (1971) Soft tissue sarcomas involving the extremities and the limb girdles: a review. South Med J 64:33-44
92. Troncone L, Galli G (eds) (1991) The role of 131-I-MIBG in the treatment of neural crest tumor. Proceedings of an international workshop, Rome, September 6-7. J Nucl Biol Med 35:177-363
93. Vernon CB, Eary JF, Rubin BP, Conrad EU, Schuetze S (2003) FDG PET imaging guided re-evaluation of histopathological response in a patient with high-grade sarcoma. Skeletal Radiol 32(3):139-142
94. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fischer S (1991) Fluorine-18-2-deoxy-2-fluoro-D-glucose (FDG) uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 67:1544-1549
95. Wallner KE, Galieich JH, Malkin MG, Arbit E, Korl G, Rosenblum MK (1989) Inability of computed tomography appearance of recurrent malignant astrocytoma to predict survival following reoperation. J Clin Oncol 7:1492-1496
96. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with 131I metaiodobenzylguanidine. J Nucl Med 21:349-353
97. Wiggins J, Goldstein H, Weinmann H (1991) Gallium-67/stable gadolinium antagonism. J Nucl Med 32:1830-1831
98. Zhang H, Tian M, Oriuchi N, Higuchi T, Watanabe H, Aoki J, Tanada S, Endo K (2003) 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun 24(3):273-279